Madrigal Pharma (MDGL) Misses Q4 EPS by 44c

Madrigal Pharma (NASDAQ: MDGL) reported Q4 EPS of ($5.68), $0.44 worse than the analyst estimate of ($5.24).

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Citi initiates Madrigal Pharmaceuticals coverage with Buy rating
• Aytu BioScience (AYTU) Tops Q4 EPS by 28c
• Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'